---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-061230"
form_type: "8-K"
ticker: "PTPI"
cik: "0001815903"
company_name: "Petros Pharmaceuticals, Inc."
filed_at: "2025-06-20T23:59:59+00:00"
generated_at: "2026-05-19T01:42:42.763608+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Petros Pharmaceuticals assigns subsidiary assets (Metuchen, Timm, Pos-T-Vac) to creditor trust

## Summary
- Effective June 16, 2025, Petros assigned all assets of subsidiaries Metuchen, Timm Medical, and Pos-T-Vac to a third-party fiduciary for benefit of creditors.
- The Vivus License Agreement for Stendra® was terminated March 31, 2025; Petros lost all rights to Stendra in the Licensed Territory.
- Pro forma balance sheet shows stockholders' equity of $8.0M as of March 31, 2025, reflecting deconsolidation, warrant exercises, and redemptions.
- Subsidiaries' operations classified as discontinued; deconsolidation from Petros' balance sheet expected in Q2 2025.

## SEC filing metadata
- accession: 0001104659-25-061230
- form_type: 8-K
- ticker: PTPI
- cik: 0001815903
- company_name: Petros Pharmaceuticals, Inc.
- filed_at: 2025-06-20T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815903/000110465925061230/0001104659-25-061230-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815903/000110465925061230/tm2518572d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-061230
- JSON: https://secwatch.observer/filing/0001104659-25-061230.json
- Plain text: https://secwatch.observer/filing/0001104659-25-061230.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.